Issue link: https://www.e-digitaleditions.com/i/377863
industry news Sustained-release topical cold sore tablet hits market CHARLESTON, SC—Dermato - logical medicine company Innocutis has begun sales of Sitavig, a slowly dis- solving tablet that adheres to the gum nearest to a cold sore on the lip. The tablet releases 50 milligrams of acy- clovir, an antiviral commonly pre- scribed to treat herpes simplex infec- tion, the cause of cold sores. In clinical trials, the tablet, when applied once over the life of the cold sore, shortened duration of cold sore epi sodes and delayed recurrence by an average of 105 days. Kansas State breaks ground on bulk solids center SALINA, KS—Kansas State Uni - versity began construction of a 13,000- square-foot research center dedicated to bulk solids materials handling. The center, expected to open by April 2015, is a collaborative effort by the university, local chamber of com- merce, and state and city govern- ments. Two local companies, Co - perion K-Tron and Vortex Valves, are supporting the project and will serve as anchor occupants. Purdue Pharma to build solid dosage plant in Durham STAMFORD, CT—Purdue Pharma Manufacturing has contracted KBR Building Group, Houston, TX, to build an oral solid dosage manufac- turing plant in Durham, NC. The 188,000-square-foot facility will fea- ture clean rooms, administrative offices, laboratories, and conference, dining, and training areas. FDA approves Merck's new type of sleep tablet WASHINGTON, DC—The FDA approved Belsomra (suvorexant) tab - lets to treat insomnia. Manu fac tured by Merck, Whitehouse Station, NJ, the tablets are the first orexin receptor antagonist to obtain approval. Orex ins are chemicals that help regulate the sleep-wake cycle and play a role in keeping people awake. Belsomra alters the signaling action of orexin in the brain. It was approved in four strengths: 5, 10, 15, and 20 milligrams. FDA approves BI's tablet to treat type 2 diabetes WASHINGTON, DC—The FDA approved Jardiance (empagliflozin) tablets to improve glycemic control in adults with type 2 diabetes, which accounts for about 90 percent of the approximately 26 million people diagnosed with the condition in the USA. The product is manufactured by Boehringer Ingelheim Phar - maceuticals, Ridgefield, CT. Known as a sodium glucose co-transporter 2 inhibitor, it blocks re-adsorption of glucose by the kidney. 8 September 2014 Tablets & Capsules Slat Fillers and Slats Available Full Packaging Line Components and Integration Modular Packaging Systems 6 Aspen Dr. Randolph, NJ 07869 P: 973-970-9393 www.modularpackaging.com Contact: Erik Bronander Model VC-12 Electronic Counter CHANNEL COUNTER/FILLER • 12 Channel Operation with speeds up to 50bpm • Fills Tablets, Capsules and Softgels • Fast Delivery